niacinamide has been researched along with Carcinoma, Medullary in 13 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sorafenib treatment was associated with Cushing's syndrome remission, elevated progesterone (>10 fold), normalization of dehydroepiandrostenedione sulfate, but persistently elevated cortisol concentration." | 7.81 | Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr ( Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW, 2015) |
| " Sorafenib treatment was associated with Cushing's syndrome remission, elevated progesterone (>10 fold), normalization of dehydroepiandrostenedione sulfate, but persistently elevated cortisol concentration." | 3.81 | Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr ( Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW, 2015) |
| " The most common treatment-related adverse events were diarrhea (41%), fatigue (41%), hypothyroidism (29%), hypertension (27%), and anorexia (27%)." | 2.74 | Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. ( Bastholt, L; Daumerie, C; Droz, JP; Elisei, R; Eschenberg, MJ; Jarzab, B; Juan, T; Locati, LD; Martins, RG; Pacini, F; Schlumberger, MJ; Sherman, SI; Stepan, DE; Sun, YN; Wirth, LJ, 2009) |
| "Medullary thyroid carcinoma has a worse prognosis, especially in patients with diffused cancers at the time of initial surgery." | 2.45 | Targeted molecular therapies in thyroid carcinoma. ( Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P, 2009) |
| "Treatment of patients with thyroid cancer is usually successful, and most patients are cured of the disease." | 2.42 | How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. ( Fagin, JA, 2004) |
| " Motesanib concentrations were fitted to a 2-compartment population pharmacokinetic model." | 1.36 | Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. ( Bruno, R; Claret, L; Kuchimanchi, M; Lu, JF; Melara, R; Sun, YN; Sutjandra, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hammami, MM | 1 |
| Duaiji, N | 1 |
| Mutairi, G | 1 |
| Aklabi, S | 1 |
| Qattan, N | 1 |
| Abouzied, Mel-D | 1 |
| Sous, MW | 1 |
| Schlumberger, MJ | 3 |
| Elisei, R | 1 |
| Bastholt, L | 1 |
| Wirth, LJ | 1 |
| Martins, RG | 1 |
| Locati, LD | 1 |
| Jarzab, B | 1 |
| Pacini, F | 1 |
| Daumerie, C | 1 |
| Droz, JP | 1 |
| Eschenberg, MJ | 1 |
| Sun, YN | 2 |
| Juan, T | 1 |
| Stepan, DE | 1 |
| Sherman, SI | 2 |
| Romagnoli, S | 1 |
| Moretti, S | 1 |
| Voce, P | 1 |
| Puxeddu, E | 1 |
| Lam, ET | 1 |
| Ringel, MD | 1 |
| Kloos, RT | 1 |
| Prior, TW | 1 |
| Knopp, MV | 1 |
| Liang, J | 1 |
| Sammet, S | 1 |
| Hall, NC | 1 |
| Wakely, PE | 1 |
| Vasko, VV | 1 |
| Saji, M | 1 |
| Snyder, PJ | 1 |
| Wei, L | 1 |
| Arbogast, D | 1 |
| Collamore, M | 1 |
| Wright, JJ | 1 |
| Moley, JF | 1 |
| Villalona-Calero, MA | 1 |
| Shah, MH | 1 |
| Fagin, JA | 2 |
| Tuttle, RM | 1 |
| Pfister, DG | 1 |
| Machens, A | 1 |
| Dralle, H | 1 |
| Bass, MB | 1 |
| Davis, MT | 1 |
| Kivman, L | 1 |
| Khoo, HM | 1 |
| Notari, KH | 1 |
| Peach, M | 1 |
| Hei, YJ | 1 |
| Patterson, SD | 1 |
| Lu, JF | 1 |
| Claret, L | 1 |
| Sutjandra, L | 1 |
| Kuchimanchi, M | 1 |
| Melara, R | 1 |
| Bruno, R | 1 |
| Prazeres, H | 1 |
| Couto, JP | 1 |
| Rodrigues, F | 1 |
| Vinagre, J | 1 |
| Torres, J | 1 |
| Trovisco, V | 1 |
| Martins, TC | 1 |
| Sobrinho-Simões, M | 1 |
| Soares, P | 1 |
| Aller, S | 1 |
| Popescu, A | 1 |
| Rao, S | 1 |
| Morgan, E | 1 |
| Gosiengfiao, Y | 1 |
| Missana, A | 1 |
| Meyer, P | 1 |
| Hong, D | 1 |
| Ye, L | 1 |
| Gagel, R | 1 |
| Chintala, L | 1 |
| El Naggar, AK | 1 |
| Wright, J | 1 |
| Kurzrock, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer[NCT02363647] | 10 participants (Actual) | Interventional | 2015-01-31 | Terminated (stopped due to No Current Funding) | |||
| Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials[NCT06079723] | 500 participants (Anticipated) | Observational | 2024-11-30 | Not yet recruiting | |||
| A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma[NCT01813136] | Phase 2 | 168 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer[NCT00121628] | Phase 2 | 184 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niacinamide and Carcinoma, Medullary
| Article | Year |
|---|---|
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Huma | 2009 |
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Human | 2004 |
4 trials available for niacinamide and Carcinoma, Medullary
| Article | Year |
|---|---|
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Medullary; Female; Humans; Indoles; Male; Middle Aged | 2009 |
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Disea | 2010 |
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Medullary; | 2010 |
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates | 2011 |
7 other studies available for niacinamide and Carcinoma, Medullary
| Article | Year |
|---|---|
Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr
Topics: Adult; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Medullary; Cushing Synd | 2015 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, | 2010 |
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Ca | 2010 |
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Medullary; Drug Administration Sche | 2010 |
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple | 2012 |
[Endocrinology].
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clini | 2012 |
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Lin | 2008 |